Acute lymphoblastic leukemia UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response Abstract Despite the pivotal role of MYC in tumorigenesis, the mechanisms by which it promotes cancer aggressiveness remain incompletely understood. Here, we show that MYC transcriptionally upregulates the ubiquitin fusion degradation 1 (UFD1) gene in T-cell acute lymphoblastic leukemia (T-ALL). Allelic loss of ufd1 in zebrafish induces tumor cell apoptosis and impairs MYC-driven T-ALL progression but does not affect general health. As the E2 component of an endoplasmic reticulum (ER)-associated degradation (ERAD) complex, UFD1 facilitates the elimination of misfolded/unfolded proteins from the ER. We found that UFD1 inactivation in human T-ALL cells impairs ERAD, exacerbates ER stress, and induces apoptosis. Moreover, we show that UFD1 inactivation promotes the proapoptotic unfolded protein response (UPR) mediated by protein kinase RNA-like ER kinase (PERK). This effect is demonstrated by an upregulation of PERK and its downstream effector C/EBP homologous protein (CHOP), as well as a downregulation of BCL2 and BCLxL. Indeed, CHOP inactivation or BCL2 overexpression is sufficient to rescue tumor cell apoptosis induced by UFD1 knockdown. Together, our studies identify UFD1 as a critical regulator of the ER stress response and a novel contributor to MYC-mediated leukemia aggressiveness, with implications for targeted therapy in T-ALL and likely other MYC-driven cancers.
Introduction
Enhanced MYC activity contributes to malignant transformation, maintenance, and progression in over half of all human cancers, including leukemias, lymphomas, and carcinomas [1] . T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy of developing thymocytes that afflicts both children and adults [2] . In over 60% of T-ALL cases, MYC is overexpressed downstream of activated NOTCH1 mutations and has a pivotal role in disease induction and aggressiveness [3] [4] [5] [6] [7] . Despite a range of treatment improvements, 15-20% of pediatric and 50% of adult patients with T-ALL succumb to disease [2] . Moreover, current multiagent protocols often cause serious systemic toxicities, underscoring the need for better therapy [8] . Improved understanding of the molecular mechanisms that underlie MYC-mediated leukemia aggressiveness may provide strategies for development of effective targeted treatments.
It has been demonstrated that enhanced MYC activity leads to cellular changes associated with a global increase in gene transcription and protein synthesis [9] [10] [11] . One consequence of this effect is an increase in misfolded/unfolded polypeptides in the endoplasmic reticulum (ER), referred to as ER stress [12] . In order to restore protein homeostasis in the ER, a number of stress response pathways are activated, including the unfolded protein response (UPR) and ERassociated degradation (ERAD) pathways [13] . The UPR is a well-conserved pathway among vertebrate species that inhibits general protein translation and upregulates specific ER chaperones to alleviate ER stress. ERAD functions downstream of the UPR to facilitate the degradation of misfolded/unfolded proteins and thus helps to restore ER protein homeostasis [13] . Although optimal cell function and survival depend on the coordinated functions of both UPR and ERAD [14] , it remains unclear how these pathways cooperate to promote tumor induction and progression.
In cells with elevated ER stress, at least three types of ER stress transducers can be activated through the release of inhibitory binding by glucose-regulated chaperone protein (GRP78/BIP): the protein kinase RNA-like ER kinase (PERK), the inositol-requiring enzyme 1 (IRE1), and the activating transcription factor 6 (ATF6) [15, 16] . Each transducer communicates ER stress to the cytosol and the nucleus to alter gene transcription, protein synthesis, and protein degradation [15, 16] . Although the UPR is often cytoprotective, it can become cytotoxic when there is prolonged and unresolved ER stress, thus serving as a central a Gene set enrichment analysis of publically available data sets revealed that a previously defined ER stress signature is significantly enriched in T-ALL patient samples, compared with normal T cells (P = 0.01; n = 53 and 21, respectively). b Gene expression heatmap for MYC, genes in three branches of the UPR pathway, and genes encoding the major ERAD complex (UFD1, NPL4, and P97) from the same data sets analyzed in a. c Western blot analysis (left panel) of MYC, ATF6, P-PERK (phospho-PERK), PERK, UFD1, NPL4, and P97 in thymus (denoted as blue) and primary T-ALL patient samples with high (denoted as red) or low (denoted as purple) MYC expression. Protein quantification (right panel) revealed that MYC-high T-ALL patient samples have higher expression levels of UFD1 but not NPL4 or P97, compared with MYC-low tumor samples (mean ± SD of UFD1 to ACTIN ratio: 0.39 ± 0.08 vs. 0.08 ± 0.002, P = 0.028; NPL4 to ACTIN ratio: 0.12 ± 0.02 vs. 0.06 ± 0.02, P = 0.154; and P97 to ACTIN ratio: 0.21 ± 0.04 vs. 0.18 ± 0.06, P = 0.63; n = 6 for MYC-high and 3 for MYC-low T-ALL patient samples)
regulator of cell fate [12] . Identification of genes controlling this switch could deepen our understanding of the regulation of the ER stress response pathways and reveal new strategies for cancer treatment.
Here we identify the ubiquitin fusion degradation 1 (UFD1) protein as a novel mediator of MYC-driven leukemia aggressiveness and a suppressor of the cytotoxic UPR. Our genomic and biochemical analyses of human patient samples pinpoint UFD1 as a MYC-activated protein that is significantly upregulated in T-ALL. UFD1 functions in a major ERAD complex downstream of the UPR to retrotranslocate unfolded/misfolded proteins from the ER lumen to the cytosol for proteasome-mediated degradation [17] . We demonstrate that UFD1 inactivation impairs ERAD, exacerbates ER stress, and activates the PERKmediated proapoptotic UPR to induce tumor cell apoptosis. Disruption of UFD1 function suppresses MYC-driven leukemia progression in vivo and kills human MYCdependent T-ALL cells in vitro. Our studies thus identify UFD1 as a key mediator of MYC-driven T-ALL progression, and suggest that a targeted therapy strategy based on these findings could improve the outlook for patients with MYC-associated, high-risk T-ALL and perhaps those with other MYC-driven cancers as well.
Results
Human T-ALL cells show elevated levels of ER stress and upregulate UFD1 in a MYC-dependent manner Aberrant MYC activity promotes gene transcription and protein translation, leading to an accumulation of misfolded/ unfolded polypeptides in the ER (i.e., ER stress) [10, 11] . and Ufd1 to Actin ratio: 0.44 ± 0.29 for normal thymus, 2.54 ± 0.47 for lymphoma cells, and 6.52 ± 1.35 for leukemic cells, P = 0.018 for thymus vs. lymphoma cells; P = 0.049 for lymphoma vs. leukemic cells; P = 0.012 for normal thymus vs. leukemic cells; n = 3 per group). c qRT-PCR analysis revealed elevated ufd1 transcript levels in Myc-overexpressing T-ALL cells from each individual fish (Myc;ufd1 +/+), compared with normal thymus dissected from each control fish (EGFP;ufd1+/+; Mean ± SD of ufd1 to β-actin ratio: 4.08 ± 0.77 vs. To determine the level of ER stress in human MYCdependent T-ALL cells, we utilized publicly available databases to compare gene expression profiles between primary human T-ALL and normal T-cell samples (GSE33470 and GSE42328) [18] . Gene set enrichment analysis (GSEA) of these data sets revealed that human T-ALL cells are significantly enriched for a previously defined ER stress signature ( Fig. 1a and Supplementary Figure 1 ) [19] , indicative of elevated ER stress in these tumor cells. To understand how T-ALL cells cope with ER stress, we analyzed the expression of genes involved in all three branches of the UPR [20] , as well as components of the major ERAD complex (UFD1, nuclear protein localization-4 [NPL4], and the valosin-containing protein P97) in human T-ALL samples and normal T cells [17] . Strikingly, the transcript levels of all UPR/ERAD-related genes analyzed, except IRE1α, were significantly elevated in human T-ALL samples compared with normal T cells (Fig. 1b) .
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Next, we analyzed protein levels of the UPR components and the UFD1-NPL4-P97 ERAD complex. As expected [7, 21] , protein levels of MYC and phospho/total PERK, but not ATF6 or IRE1α, were increased in most primary T-ALL samples ( Fig. 1c and Supplementary Figure 2) . Surprisingly, among the three UFD1-NPL4-P97 ERAD components, only UFD1 was significantly upregulated in MYCoverexpressing T-ALL samples, compared with those with lower MYC expression (Fig. 1c) . Finally, we performed western blot analysis on a panel of human MYC-dependent T-ALL cell lines to detect protein levels of the above UPR and ERAD components. Consistent with what we observed in MYC-overexpressing patient samples, MYC and UFD1 were significantly upregulated in human T-ALL cell lines, compared with control thymus (Supplementary Figure 3) . In addition, we observed upregulation of phospho/total PERK and ATF6 in some of human MYC-dependent T-ALL cell lines, indicative of ER stress. Together, our studies demonstrate that human T-ALL cells are primed with ER stress and upregulate UFD1 in a MYC-dependent manner.
MYC transcriptionally regulates UFD1 in human leukemic cells
To determine whether MYC regulates UFD1, we inactivated MYC by short hairpin RNA (shRNA) in human BCL2-overexpressing and thus apoptosis-resistant JURKAT T-ALL cells. Western blotting revealed that UFD1, but not P97 or NPL4, was downregulated in these cells upon MYC knockdown (Fig. 2a) . MYC inactivation also suppressed PERK-mediated UPR, as demonstrated by decreased expression of phospho/total PERK and its downstream effector C/EBP homologous protein (CHOP), whereas minimally affecting ATF6 and IRE1α (Fig. 2a) . Similar to MYC knockdown, inactivation of TAL1, another major T-ALL oncogene, also downregulated phospho/total PERK and CHOP, but did not decrease UFD1 protein levels, suggesting that UFD1 is specifically regulated by MYC but not TAL1 or PERK (Fig. 2a) . To understand if MYC regulates UFD1 transcriptionally, we performed firefly luciferase assays to measure UFD1 promoter activity in BCL2-overexpressing JURKAT T-ALL cells. MYC inactivation significantly reduced UFD1 promoter activity, leading to a reduced expression of the luciferase reporter gene (Fig. 2b) . Next, we performed chromatin-immunoprecipitation (ChIP) PCR in human JURKAT T-ALL cells and found that MYC binds to the promoter region of UFD1 (Fig. 2c) . Finally, analysis of published ChIP-Seq data, from experiments designed to identify MYC-binding sites in human JURKAT and K562 leukemic cells [22, 23] , further demonstrated that MYC binds to the promoter region of UFD1 (Supplementary Figure 4 ). Analyses of human ENCODE databases revealed three MYC-binding elements, including a conserved E-box motif, in the promoter region of UFD1. Together, our data indicate that MYC transcriptionally upregulates UFD1 in human leukemic cells.
MYC drives continuous upregulation of ufd1 during T-ALL development in vivo
To gain insight into the in vivo importance of UFD1 during MYC-mediated leukemogenesis, we studied a zebrafish model of T-ALL that overexpresses EGFP-fused mammalian Myc from a lymphocyte-specific promoter (rag2) and resembles a major subtype of human disease [24, 25] . Western blot analysis was performed to detect Ufd1 and EGFP-MYC protein levels in the normal thymus from control Tg(rag2:EGFP) fish (EGFP) versus tumor cells from Tg(rag2:EGFP-mMyc) fish (Myc) at stages of disease onset and dissemination (Fig. 3a) . Compared with the control thymus, Ufd1 protein levels were significantly elevated in Myc-overexpressing T-ALL cells at disease onset and continued to increase as the tumors progressed, a pattern similar to that of EGFP-MYC protein levels (Fig. 3a,  b) . Bip protein levels were also elevated in these Mycoverexpressing T-ALL cells, compared with control thymocytes (Supplementary Figure 5a) , indicating elevated ER stress. Consistent with our observation in human patient samples, qRT-PCR analysis demonstrated a significant upregulation of perk but not atf6 transcript levels in these Myc-overexpressing T-ALL cells, compared with control thymocytes (Supplementary Figure 5b) . As in human T-ALL cells (Figs. 1b, 2) , the increase in Ufd1 protein levels was also driven by MYC-induced transcription in vivo, as shown by qRT-PCR analysis of ufd1 transcript levels in control thymocytes (EGFP;ufd1+/+) and Myc-overexpressing T-ALL (Myc;ufd1+/+) cells (left panel of Fig. 3c ). To address whether continued upregulation of ufd1 depends on MYC, we analyzed the Tg(rag2:MYC-ER);Tg (rag2:EGFP-bcl2) zebrafish line, in which MYC activity is conditionally regulated by 4-hydroxytamoxifen (4-HT) and bcl2 overexpression precludes apoptosis upon MYC inactivation [26] . Indeed, ufd1 transcript levels were significantly downregulated as early as 24 h after 4-HT removal (right panel of Fig. 3c ). These data indicate that MYC activity accounts for the elevated ufd1 expression observed during T-ALL development.
Heterozygosity of ufd1 decreases MYC-induced T-ALL burden and delays tumor progression without affecting animal health
To determine whether UFD1 is essential for MYC-driven T-ALL pathogenesis, we studied the zebrafish ufd1 hi3471 mutant line [27] , which harbors a retroviral insertion in the 5′ UTR region of the ufd1 gene, leading to disruption of transcription and loss of gene expression. After breeding the ufd1 heterozygous fish to the stable Myc transgenic fish, we observed a significant reduction of tumor burden in the Myc;ufd1+/− fish versus their Myc;ufd1+/+ siblings (right panels of Fig. 4a, b) . Notably, ufd1 heterozygosity did not affect non-transformed thymocytes in the control EGFP fish (compare fluorescence intensity of EGFP;ufd1+/+ vs. EGFP;ufd1+/− in left panels of Fig. 4a, b) . Western blot analysis confirmed a 50% reduction of Ufd1 protein levels in both control EGFP;ufd1+/− thymocytes and Myc;ufd1 +/− lymphoblasts, although Ufd1 protein levels in tumor cells were significantly higher than control thymocytes regardless of ufd1 mutational status ( Supplementary  Figures 6a-b) . Next, we asked whether disruption of UFD1 function could inhibit T-ALL progression. For this purpose, we chose Tg(rag2:loxp-dsRED2-loxp-EGFP-mMyc);Tg (hsp70-Cre) fish (designated as Myc;Cre) [28] , which develop T-ALL more slowly and with a wider window of time than the stable Myc (Tg[rag2:EGFP-mMyc]) line (45-250 vs. 35-60 days of life), permitting delineation of tumor onset and disease progression [28, 29] . We then bred ufd1 heterozygous fish to the Myc;Cre double transgenic fish, subjected their progeny to heat-shock treatment to induce Myc expression, and monitored the fish for the time of tumor onset and progression as previously described [28, 29] . Despite no effect on tumor onset (Supplementary (Fig. 4c, d) . By 399 days of life, 78% of the Myc;Cre;ufd1+/+ fish with tumor had wide T-ALL dissemination, in marked contrast to only 37% of the Myc; Cre;ufd1+/− fish with the disease (Fig. 4d ).
An important question was whether the reduced Ufd1 activity would impede normal development. A visual screen of the progeny of ufd1 heterozygotes at 4, 6, and 9 days post fertilization (dpf) failed to detect any morphologic or hematopoietic defects in these fish (ufd1+/−; Supplementary Figures 7a-b , middle panels), compared with wild-type siblings (ufd1+/+; Supplementary Figures 7a-b , left panels). However, ufd1 homozygous mutants (ufd1-/-) exhibited developmental defects starting at 4 dpf (e.g., jaw protrusion) and failed to develop swim bladders at 6 dpf, despite apparently normal hematopoietic development (Supplementary Figures 7a-b, right panels) . By 9 dpf, none of the ufd1-/-fish remained viable. Consistent with their lack of morphologic defects during embryonic stages, ufd1 heterozygous fish were viable and grew at similar rates as their wild-type siblings into adulthood in the expected Mendelian ratios (Supplementary Figure 8a) . Finally, histologic analysis of serial Hematoxylin & Eosin-stained sections of 4-month-old ufd1+/+ and ufd1+/− siblings did not reveal any gross abnormalities in multiple tissues and organs from the heterozygous fish, including eye, brain, thymus, kidney, heart, liver, ovary, testis, intestine, and muscle (Supplementary Figure 8b and data not shown). These data demonstrate that ufd1 heterozygosity inhibits MYC-induced T-ALL pathogenesis without impairing normal fish development.
To elucidate the cellular basis for this effect, we performed immunofluorescent staining for active caspase-3 to detect possible apoptotic cells in four groups of cells: EGFP;ufd1+/+ and EGFP;ufd1+/− thymocytes, as well as Myc;ufd1+/+ and Myc;ufd1+/− lymphoblasts (Fig. 5a ). Active caspase-3 staining revealed a significantly higher number of apoptotic cells among the Myc;ufd1+/− T-ALL cells, compared with control thymocytes or Myc;ufd1+/+ T-ALL cells (Fig. 5a, b) . Similarly, Annexin-V/PI (propidium iodide) staining of these cells also revealed increased apoptotic cells in Myc;ufd1+/− T-ALL cells (Supplementary Figure 9a ). To understand how ufd1 loss affects cell proliferation, we performed PI staining and flow cytometry analysis to examine DNA content in control EGFP;ufd1 +/+ and EGFP;ufd1+/− thymocytes, as well as Myc;ufd1 +/+ and Myc;ufd1+/− T-ALL cells. Heterozygous loss of ufd1 did not cause any cell cycle changes in non- Figures 9b-c) . However, Myc;ufd1+/− tumor cells showed a significant increase in G0/G1-phase cells and a reduction of cells in S and G2 phase, compared with Myc;ufd1+/+ T-ALL cells or EGFP;ufd1+/− control thymocytes (right panel of Fig. 5c , and Supplementary Figures 9b-c ). Our data demonstrate that ufd1 heterozygosity induces apoptosis and decreases proliferation in Myc-overexpressing T-ALL cells but not in normal thymocytes.
UFD1 inactivation exacerbates ER stress, decreases cell growth, and induces apoptosis in human MYCdependent T-ALL cells
Our findings thus far suggest that targeting UFD1 could efficiently impair the ability of leukemic T cells to cope with ER stress, leading to their apoptotic death. To test this hypothesis in human leukemic cells, we genetically inactivated UFD1 in JURKAT, MOLT3, and PEER cell lines, using two previously published shRNA hairpins (shUFD1 #1 and #2; see western blotting insert in Figs. 6a, 7a , and left panel of Supplementary Figure 10c ) [30] , as well as two hairpins that target the 3′ untranslated region of the gene and reduce~80% of UFD1 protein levels (shUFD1 #3 and #4; see western blotting inserts in Supplementary Figure 10a and right panel of Supplementary Figure 10c) . UFD1 knockdown by shRNAs significantly induced ER stress, as demonstrated by increased thioflavin staining (Supplementary Figure 11) and elevated BIP levels in human T-ALL cells (Fig. 7a and Supplementary Figure 10c ) [31] [32] [33] . Moreover, these shRNAs significantly reduced the growth of all three T-ALL cell lines, with a stronger knockdown leading to a more severe inhibition of growth, compared with control cells transduced with shLuciferase ( Fig. 6a and Supplementary Figures 10a-b) . To assess the (Fig. 6b) . Cell cycle analysis at day 4 post infection revealed that UFD1 knockdown induced a modest but significant accumulation of G1-phase cells and a reduction of S-phase cells in JURKAT T-ALL cells (Fig. 6c) . These data support the concept that human T-ALL cells depend on elevated UFD1 protein levels to cope with ER stress, and indicate the potential of targeting this protein as a therapeutic option in high-risk cases.
UFD1 inactivation impairs ERAD and activates the PERK-mediated proapoptotic UPR in human T-ALL cells
UFD1 functions in the major ERAD complex downstream of the UPR to facilitate the retrotranslocation of misfolded/ unfolded proteins from the ER lumen to the cytosol for proteolysis [17] . We thus performed western blotting to examine the protein levels of ERAD substrates and UPR components in human T-ALL cells [20, 34] . UFD1 knockdown led to elevated levels of CD3δ (a known ERAD substrate of UFD1) [35] , ATF6, phospho/total PERK, but not phospho/total IRE1α in JURKAT, MOLT3, and PEER T-ALL cell lines (Fig. 7a, Supplementary Figure 10c , and data not shown). As expected, due to the difference in response kinetics of ER stress transducers [36] , the expression levels of these proteins varied at different time points upon UFD1 inactivation in each cell line. However, all three T-ALL cell lines upregulated phospho-and/or total PERK upon UFD1 inactivation. In addition, we observed upregulation of CHOP, a downstream effector of the PERKmediated proapoptotic UPR [37] . Because CHOP activation leads to downregulation of the antiapoptotic protein BCL2 and subsequent activation of ER stress-induced apoptosis [38] , we performed western blotting to analyze protein levels of BCL2, BCLxL, and cleaved PARP. Indeed, UFD1 knockdown led to downregulation of BCL2 and BCLxL, as well as an increase in cleaved PARP in all three T-ALL cell lines tested, compared with control cells with shLuciferase knockdown (Fig. 7a and Supplementary Figure 10c ). To determine whether the PERK-CHOP-BCL2 axis is crucial to the growth and survival of human T-ALL cells, we transduced human JURKAT and MOLT3 cells with shCHOP and shUFD1, alone or in combination, and measured cell growth from day 4 to 12 post infection. As expected, knockdown of UFD1 alone induced apoptosis and a significant decrease in cell growth, compared with control cells infected with shLuciferase ( Fig. 7b and data not shown). Although shCHOP alone slightly decreased cell growth, the combined knockdown of CHOP and UFD1 led to upregulation of BCL2 and rescue of the decreased cell growth (Fig. 7b and data not shown) . Overexpressing BCL2, a downregulated gene in the CHOP-mediated apoptotic axis, had the same effect in completely rescuing the decreased cell growth induced by UFD1 knockdown (Fig. 7c ). These results demonstrate that UFD1 inactivation in MYC-dependent T-ALL cells disrupts ERAD and primarily induces the proapoptotic UPR through the PERK-CHOP-BCL2 axis.
Discussion
Tumor progression is facilitated by a number of adaptive mechanisms that enable malignant cells to survive and proliferate in a hostile microenvironment [39] [40] [41] . Together with oncogenic stress, the adverse microenvironmental conditions, such as free radicals, low oxygen, nutrient deprivation, pH imbalance, and reactive oxygen species, all severely burden the ER with misfolded/unfolded proteins (see Fig. 8 ). The ER quality control system, including the UPR and ERAD, is therefore critical for enabling cells to cope with ER stress [13] . Although others have demonstrated that MYC-dependent lymphoma and breast cancer cells activate the UPR to support tumor cell survival [21, 42] , whether MYC regulates ERAD remains unclear. Our findings show that whereas MYC-overexpressing T-ALL cells activate the UPR, they simultaneously enhance ERAD through transcriptional upregulation of UFD1 to support leukemic cell survival. UFD1 inactivation in MYCdependent T-ALL cells led to an accumulation of its ERAD substrate CD3δ, indicative of defective ERAD function, and exacerbation of ER stress, as demonstrated by increased thioflavin T staining and BIP expression. Importantly, ufd1 heterozygosity induced tumor cell apoptosis and significantly impaired disease progression in the zebrafish model of MYC-induced T-ALL. Together, our results support the working model that MYC-enhanced expression of UFD1 promotes ERAD and mitigates ER stress, cooperating with the UPR to sustain tumor cell survival and disease progression (Fig. 8a) . Hence, our studies identify UFD1 as a novel contributor to MYC-mediated cancer aggressiveness.
The role of the UPR in supporting tumor cell survival is of great interest for therapeutic exploitation in multiple human cancers [43] . Interestingly, MYC-overexpressing T-ALL cells primarily activate the PERK-mediated UPR. Although translation inhibition mediated by PERK activation can induce leukemic cell apoptosis [44, 45] , we found that the decreased cell growth upon UFD1 inactivation was fully rescued through downregulation of CHOP or overexpression of BCL2, both of which are downstream effectors of the PERK-mediated proapoptotic UPR. Thus, UFD1 inactivation in MYC-dependent T-ALL cells induces apoptosis primarily through the PERK-CHOP-BCL2 axis instead of through PERK-mediated translation inhibition or the ATF6-mediated UPR. Earlier studies focused on targeting the PERK-mediated UPR as an anti-neoplastic approach. However, PERK inhibitors were found to be highly toxic and cause diabetes [44] . We show that a 50% reduction of UFD1 protein induces robust apoptosis and slows proliferation in T-ALL cells but not in non- transformed thymocytes. Underlying this difference is that non-malignant cells do not or minimally experience ER stress, while T-ALL cells are burdened with ER stress due to MYC overexpression and hostile microenvironmental conditions. Our findings support the notion that UFD1 inhibition could serve as a productive approach to activate the PERK-mediated proapoptotic UPR and kill MYCdependent tumor cells while minimally affecting normal cells (Fig. 8b) .
Among the three ERAD components, we found that MYC selectively upregulates UFD1 but not P97 or NPL4. Although the involvement of P97 in cancers has been previously demonstrated [45] , how P97 promotes tumorigenesis remains elusive. Our studies suggest that the contribution of P97 to MYC-driven tumor development is largely mediated through UFD1. The enhanced UFD1 expression can compete P97 away from other adaptor proteins to enhance its ERAD function. Although P97 inhibitors show preclinical anti-neoplastic efficacy, they likely possess off-target toxicities given that P97 interacts with a myriad of adaptors beyond UFD1 [46] . Importantly, the enhanced UFD1 expression is observed in multiple human MYC-driven cancers besides T-ALL [47, 48] , and predicts poor treatment outcome in ER + breast cancer and lung cancer (http://kmplot.com/analysis/). Therefore, besides treating MYC-overexpressing refractory/relapsed T-ALL, the therapeutic potential of directly targeting UFD1 could extend to patients with a broad spectrum of MYC-driven cancers, supporting the need to develop UFD1-specific inhibitors.
Materials and methods

Zebrafish husbandry, tumor surveillance, and genotyping
Zebrafish line maintenance and husbandry were performed as previously described in the aquatics facility at the DanaFarber Cancer Institute under a subcontract and at the Boston University School of Medicine [49] , according to standards set by the National Institutes of Health (NIH) and approved protocols of the Institutional Animal Care and Use Committee. Both male and female AB fish younger than 2-year-old were included in the studies. All transgenic and mutant fish were genotyped by gene-specific PCR using primers (Supplementary Table 1 ) and DNA isolated from either the whole embryo or the tail fin of the individual adult fish as previously described [28] . Surveillance for tumor onset and progression were conducted as previously described using published criteria [29] . Tumor burden and disease stage were documented by imaging on both brightfield and EGFP/DsRED2 channels using a fluorescent microscope (MVX10; Olympus, Center Valley, PA, USA). The images were quantified with Image J software and processed with Adobe Photoshop (Adobe Systems Incorporated, San Jose, CA, USA).
Patient samples and gene expression analysis
The detailed information for patient samples is included in Supplementary Information. For gene expression analysis of patient samples, previously published gene expression data sets (GSE33470 and GSE42328) were obtained from the NCBI Gene Expression Omnibus, and reanalyzed in this study [18] . Both of the studies were carried out on the Illumina HumanHT-12 V4.0 Expression BeadChip. To compare the differential gene expression profiles between normal T cells and T-ALL patient samples, we merged data from the two series of records and applied quantile normalization to the raw data to remove sources of variation between different experiments. The GSEA system from the Broad Institute was used to analyze for the enrichment of the ER stress signature in T cells and T-ALL patient samples. We calculated an enrichment score that reflects the degree to which the gene set is overrepresented at the extremes (top or bottom) of the entire ranked list. The result is significant at false discovery rate < 25% and at nominal P-values ≤ 5%.
Firefly luciferase assay and ChIP-PCR analysis
Human T-ALL cells were transfected with LightSwitch promoter constructs for UFD1 or β-ACTIN (ACTB) (Switchgear Genomics, Carlsbad, CA, USA) at day 3 post infection. Luciferase assays were performed at 30 h post transfection using a commercial luciferase kit (Switchgear Genomics, Carlsbad, CA, USA). Human T-ALL cells were cross-linked, sonicated, and subsequently subjected to ChIP using a commercial ChIP kit (Epigentek Group Inc., Farmingdale, NY, USA), together with an anti-MYC or anti-polymerase II or anti-IgG antibody. The input and resultant ChIP DNA were subjected to PCR using two UFD1 and ACTB primers (Supplementary Table 2 ), spanning their respective promoters.
Statistical analysis
Kaplan-Meier analysis and the log-rank test were used to compare times with tumor onset and progression between Myc;Cre;ufd1+/+ and Myc;Cre;ufd1+/− fish. The sample size was determined based on data previously published [28, 29] . Student's t-test was used to analyze differences in gene expression, tumor burden, cell cycle, number of active caspase-3 + cells, protein levels, Annexin-V-stained cells, and cell viability between control and experimental group, or between any two groups of cells with different genotypes. P values ≤ 0.05 were considered statistically significant, and not adjusted for multiple comparisons.
